Panacea Biotec Unveils World’s First Fully Liquid wP-IPV Pentavalent Vaccine

EasyFourPol® stands as the first-ever fully liquid wP-IPV Pentavalent vaccine, safeguarding children against five deadly diseases including Diphtheria, Tetanus, Pertussis, Polio, and invasive infections from Haemophilus Influenza Type b.

Leading biotech player, Panacea Biotec Ltd has unveiled the world's first fully liquid wP-IPV-based Pentavalent vaccine, "EasyFourPol," in India.

EasyFourPol® stands as the first-ever fully liquid wP-IPV Pentavalent vaccine, safeguarding children against five deadly diseases including Diphtheria, Tetanus, Pertussis, Polio, and invasive infections from Haemophilus Influenza Type b.

Further, this vaccine eliminates the need for on-site preparation by healthcare workers, offering the same level of protection as single-antigen vaccines. It also streamlines vaccination processes and reduces costs thereby contributing to environmental sustainability by minimising the usage of vials, syringes, and packaging.

Sharing his views, Dr Rajesh Jain, chairman and MD, Panacea Biotec, said, "We are delighted to launch EasyFourPol® - another landmark in our innovative and first-in-class combination vaccine portfolio that makes vaccinations easier, benefits the child, parents, and doctors while helping the world meet UN Sustainable Development Goals. We are certain that Indian paediatricians and parents will continue to put their trust in Panacea Biotec to meet evergrowing vaccination needs through innovative solutions."

Additionally, its subsidiary, Panacea Biotec Germany GmbH, has successfully registered Valganciclovir 50 mg/ml Powder for Oral Solution in Germany. This medication, a cytomegalovirus DNA polymerase inhibitor, serves crucial roles in the initial and maintenance treatment of cytomegalovirus (CMV) retinitis in adults with AIDS and the prophylaxis of CMV disease in transplant recipients.

Paediatric vaccination plays an important role in achieving Sustainable Development Goals (SDGs) set by the United Nations, in particular the target to reduce the under-five mortality rate to less than 25 per 1000 live births.

Founded in 1984, Panacea Biotec is a leading biotechnology company in India that produces and markets pharmaceutical formulations, vaccines, biosimilars, and natural products. It aims to make novel products that are affordable and available to the general public.

In May 2021, Panacea Biotec tied up with the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund to produce 100 million doses of the Sputnik V COVID-19 vaccine annually in India.

In a similar development, AstraZeneca bought respiratory vaccine developer Icosavax in a $1.1 billion deal. The cash deal aimed at strengthening AstraZeneca's drugs pipeline that values US-listed Icosavax at $15 per share. Additionally, there is a provision for an additional $5 per share if specific milestones are achieved.